ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression

Lung Cancer

Volumn 91, Issue , 2016, Pages 70-72

  Ou, Sai Hong ^a,b   Milliken, Jeffrey C ^a   Azada, Michele C ^b   Miller, Vincent A ^c   Ali, Siraj M ^c   Klempner, Samuel J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FOUNDATION MEDICINE   (United States)

Author keywords

Acquired resistance; Alectinib; ALK F1174V mutation; ALK I1171S mutation; ALK inhibitor; ALK positive lung cancer; Comprehensive genomic profiling

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; CRIZOTINIB; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; EXON; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LUNG NODULE; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROCEDURES; REMISSION;

BIOPSY; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION;

EID: 84955184379     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.09.006     Document Type: Article

References (10)

1. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 37:2167-2177.
2. Awad M.M., Shaw A.T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 2014, 12:429-439.
3. Ou S.H., Azada M., Hsiang D.J., Herman J.M., Kain T.S., Siwak-Tapp C., et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J. Thorac. Oncol. 2014, 9:549-553.
4. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010, 70:10038-10043.
5. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Dis. 2014, 4:662-673.
6. Ceccon M., Mologni L., Giudici G., Piazza R., Pirola A., Fontana D., et al. Treatment efficacy and resistance mechanisms using the second-generation ALK Inhibitor AP261 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol. Cancer Res. 2015, 13:775-783.
7. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Kukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
8. Kodama T., Tsukaguchi T., Yoshida M., Kondoh O., Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014, 351:215-221.
9. Bresler S.C., Weiser D.A., Huwe P.J., Park J.H., Krytska K., Ryles H., et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014, 26:682-694.
10. Ou S.H., Greenbowe J., Khan Z.U., Azada M.C., Ross J.S., Stevens P.J., et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer 2015, 88:231-234.